Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

LIPOGEMS: Man's Best Friend Can Achieve Pain Relief and Improved Function from a Medical Device Cleared For Orthopaedics and Arthroscopic Surgery in Humans

Encouraging Results of A Multicenter Study


News provided by

Lipogems

Sep 06, 2018, 14:54 ET

Share this article

Share toX

Share this article

Share toX

NORCROSS, Va., Sept. 6, 2018 /PRNewswire/ -- Dog lovers know too well the heartbreak of helplessly standing by as their beloved, four-legged friends endure agonizing osteoarthritis (OA). But an encouraging new study strongly suggests significant osteoarthritis relief for dogs is now available from a medical technology originally developed for humans.  

Continue Reading
Gilda the German Shepard results from the Lipogems procedure
Gilda the German Shepard results from the Lipogems procedure
Lipogems successfully uses a patient’s own body fat (known clinically as adipose tissue) to assist in the healing process and, in some cases, used in conjunction with traditional orthopaedic surgery.
Lipogems successfully uses a patient’s own body fat (known clinically as adipose tissue) to assist in the healing process and, in some cases, used in conjunction with traditional orthopaedic surgery.

"Dog," the old saying goes, "is man(kind)'s best friend." But connections between dogs and people extend beyond their bond. Mankind can happily return the love and save your best friend in a meaningful new way by providing pain relief from a debilitating, all-too-common disorder.

What is Osteoarthritis, Anyway?
OA is the most common form of ache-producing arthritis and can impact all breeds, sizes and ages, with 20% of adult dogs suffering from this condition. 

Sometimes called the "bone on bone" condition, OA develops when the body's natural protective "pillow" of cartilage, located at the ends of bones, erodes over time. The resulting bone crunching seriously damages joints, especially those in the hands, knees, hips and spine. This causes OA's telltale pain, tenderness and stiffness. Dog sufferers also lose flexibility, while their joint bones grind and grate against one another. Bone spurs—extra bits of bone that feel lumpy—can develop. These tend to magnify the discomfort in an osteoarthritic joint.

The Exciting Technology Is Already Here
A new study strongly suggests that LIPOGEMS, a medical technology developed in recent years for human orthopaedic patients, can also be used for mankind's best bud. LIPOGEMS was first cleared for use in human orthopaedic procedures in 2015 by the federal Food and Drug Administration. The state-of-the-art system utilizes a patient's own adipose (fat) to support healing, either with surgery or as a minimally invasive procedure in the office.

In the minimally invasive LIPOGEMS protocol, the animals' own fat cells are removed from the flank, also-called "love handles." The richly reparative fat tissue is then specially processed to screen out unwanted blood, oils and other contaminants. The now-cleansed fat cells (called micro-fragmented adipose, or MFAT) then are injected with precision into joints restoring some of the natural cushion between the bones. The simple LIPOGEMS outpatient procedure is over in less than an hour.

Dramatic Study Findings Bring Hope for Our Dogs…and Their Veterinarians

This multicenter study was led by a noted Italian veterinarian and researcher, Dr. Offer Zeira, and was conducted at leading veterinary sites throughout Europe. The results were published in July 2018 in a peer reviewed journal, Stem Cells Translational Medicine. The study's overall purpose was to evaluate the safety, feasibility and the clinical outcomes of using LIPOGEMS to treat spontaneous osteoarthritis in dogs. The positive results should prove very encouraging to both veterinarians and dog owners.

Study Details
Overall, 130 dogs and 346 of their joints were treated, involving mostly hips, elbows and stifles. (The stifle, a dog's complex hind limb joint, is comparable to the human knee.) The degrees of OA ranged as follows:

  • Grade I—very early OA: 1.5 percent of dogs studied
  • Grade II—the beginning of cartilage cracks, growth of bone spurs, slightly inflamed joints: 30 percent
  • Grade III—moderate to severe OA: 47.7 percent
  • Grade IV—advanced OA, intense, chronic pain, frequent immobilization: 20.8 percent

Impressive Results that Make Dogs Bark For Joy

One month after the LIPOGEMS procedure, 78 percent of the four-legged friends showed measurable improvement from the initial baselines. At six months, the Zeira team identified even more encouraging numbers: 88 percent of dogs showed steady improvement in pain reduction and function; just eleven percent remained the same, and one percent worsened. Impressively, 92 percent exhibited considerable or significant improvement in behavior, gait and function. Only six percent showed slight improvement, while two percent backslid.  Notably two years after the procedure, the owners still sent in videos of their furry friends and completed the pain questionnaires.

The animals' own fat —their LIPOGEMS-treated autologous micro-fragmented adipose tissue (MFAT)—performed well.  The study found MFAT safe for the dogs, as it produced no short- or long-term adverse events or side effects at the harvesting site or where the cells were delivered. The authors found that the MFAT remained in place up to 11 months after injection to cushion the area. The MFAT stayed put allowing the body to heal the natural way. Generally, larger dogs in the study benefited more than their smaller brethren. Plus, those canines with more severe OA—grades III and IV—demonstrated greater improvement than dogs placed in the two lower grades.

The FDA has cleared the Lipogems system for general use in orthopaedic and arthroscopic surgery since 2016, however the safety and efficacy of Lipogems for specifically treating osteoarthritis in humans has not yet been evaluated or confirmed by the FDA.

One Procedure for MANY Joints—In One Simple Visit

Since fat is easy to get from the animal's love handles, the study also reported that veterinarians can successfully inject the micro-fragmented adipose tissue in multiple joints or soft tissue during a single procedure. This eliminates the need for the dog to return for multiple visits to the vet.  The authors stated that other technologies like Platelet Rich Plasma injection require the dog to come back multiple times to achieve the same results that Lipogems can accomplish in one simple visit.

Based on study findings, authors said that the "LIPOGEMS procedure is simple, time-sparing, cost-effective, and minimally invasive."

SOURCE Lipogems

Related Links

http://www.understandlipogems.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

LIPOGEMS ANNOUNCES LAST PATIENT LAST VISIT FOR ARISE 1 KNEE OSTEOARTHRITIS TRIAL

LIPOGEMS ANNOUNCES LAST PATIENT LAST VISIT FOR ARISE 1 KNEE OSTEOARTHRITIS TRIAL

Lipogems is proud to announce the completion of the ARISE I U.S. FDA IDE Study with the last patient's last visit successfully completed. This...

LIPOGEMS ANNOUNCES ENROLLMENT OF THE FINAL PATIENT IN ARISE FDA CLINICAL TRIALS FOR KNEE OSTEOARTHRITIS

LIPOGEMS ANNOUNCES ENROLLMENT OF THE FINAL PATIENT IN ARISE FDA CLINICAL TRIALS FOR KNEE OSTEOARTHRITIS

Lipogems has announced the final patient enrolled in the ARISE II U.S. FDA IDE Study, which aims to evaluate the efficacy and safety of MicroFat...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

Animal Welfare

Animal Welfare

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.